342 related articles for article (PubMed ID: 19075737)
1. Cellular delivery in vivo of siRNA-based therapeutics.
Aigner A
Curr Pharm Des; 2008; 14(34):3603-19. PubMed ID: 19075737
[TBL] [Abstract][Full Text] [Related]
2. Polyethylenimines for RNAi-mediated gene targeting in vivo and siRNA delivery to the lung.
Günther M; Lipka J; Malek A; Gutsch D; Kreyling W; Aigner A
Eur J Pharm Biopharm; 2011 Apr; 77(3):438-49. PubMed ID: 21093588
[TBL] [Abstract][Full Text] [Related]
3. Nonviral in vivo delivery of therapeutic small interfering RNAs.
Aigner A
Curr Opin Mol Ther; 2007 Aug; 9(4):345-52. PubMed ID: 17694447
[TBL] [Abstract][Full Text] [Related]
4. Nonviral pulmonary delivery of siRNA.
Merkel OM; Kissel T
Acc Chem Res; 2012 Jul; 45(7):961-70. PubMed ID: 21905687
[TBL] [Abstract][Full Text] [Related]
5. Strategies for in vivo delivery of siRNAs: recent progress.
Higuchi Y; Kawakami S; Hashida M
BioDrugs; 2010 Jun; 24(3):195-205. PubMed ID: 20462284
[TBL] [Abstract][Full Text] [Related]
6. Polyethylenimine (PEI)/siRNA-mediated gene knockdown in vitro and in vivo.
Höbel S; Aigner A
Methods Mol Biol; 2010; 623():283-97. PubMed ID: 20217558
[TBL] [Abstract][Full Text] [Related]
7. Efficient and targeted delivery of siRNA in vivo.
Shim MS; Kwon YJ
FEBS J; 2010 Dec; 277(23):4814-27. PubMed ID: 21078116
[TBL] [Abstract][Full Text] [Related]
8. Applications of RNA interference: current state and prospects for siRNA-based strategies in vivo.
Aigner A
Appl Microbiol Biotechnol; 2007 Aug; 76(1):9-21. PubMed ID: 17457539
[TBL] [Abstract][Full Text] [Related]
9. Harnessing RNA interference to develop neonatal therapies: from Nobel Prize winning discovery to proof of concept clinical trials.
DeVincenzo JP
Early Hum Dev; 2009 Oct; 85(10 Suppl):S31-5. PubMed ID: 19833462
[TBL] [Abstract][Full Text] [Related]
10. Gene silencing through RNA interference (RNAi) in vivo: strategies based on the direct application of siRNAs.
Aigner A
J Biotechnol; 2006 Jun; 124(1):12-25. PubMed ID: 16413079
[TBL] [Abstract][Full Text] [Related]
11. In vivo application of RNA interference: from functional genomics to therapeutics.
Lu PY; Xie F; Woodle MC
Adv Genet; 2005; 54():117-42. PubMed ID: 16096010
[TBL] [Abstract][Full Text] [Related]
12. Targeted Liposomes for siRNA Delivery to Cancer.
Eloy JO; Petrilli R; Raspantini GL; Lee RJ
Curr Pharm Des; 2018; 24(23):2664-2672. PubMed ID: 30084323
[TBL] [Abstract][Full Text] [Related]
13. Targeted delivery of short interfering RNAs--strategies for in vivo delivery.
Wullner U; Neef I; Tur MK; Barth S
Recent Pat Anticancer Drug Discov; 2009 Jan; 4(1):1-8. PubMed ID: 19149683
[TBL] [Abstract][Full Text] [Related]
14. In vivo gene silencing following non-invasive siRNA delivery into the skin using a novel topical formulation.
Hegde V; Hickerson RP; Nainamalai S; Campbell PA; Smith FJ; McLean WH; Pedrioli DM
J Control Release; 2014 Dec; 196():355-62. PubMed ID: 25449884
[TBL] [Abstract][Full Text] [Related]
15. Optimized polyethylenimine (PEI)-based nanoparticles for siRNA delivery, analyzed in vitro and in an ex vivo tumor tissue slice culture model.
Ewe A; Höbel S; Heine C; Merz L; Kallendrusch S; Bechmann I; Merz F; Franke H; Aigner A
Drug Deliv Transl Res; 2017 Apr; 7(2):206-216. PubMed ID: 27334279
[TBL] [Abstract][Full Text] [Related]
16. Delivery strategies for siRNA-mediated gene silencing.
Gilmore IR; Fox SP; Hollins AJ; Akhtar S
Curr Drug Deliv; 2006 Apr; 3(2):147-5. PubMed ID: 16611001
[TBL] [Abstract][Full Text] [Related]
17. [Application of atelocollagen-mediated siRNA delivery for RNAi therapies].
Honma K; Takeshita F; Ochiya T
Yakugaku Zasshi; 2007 May; 127(5):807-12. PubMed ID: 17473522
[TBL] [Abstract][Full Text] [Related]
18. Lipid-based nanoparticles for siRNA delivery in cancer therapy: paradigms and challenges.
Gomes-da-Silva LC; Fonseca NA; Moura V; Pedroso de Lima MC; Simões S; Moreira JN
Acc Chem Res; 2012 Jul; 45(7):1163-71. PubMed ID: 22568781
[TBL] [Abstract][Full Text] [Related]
19. Recent progress in development of siRNA delivery vehicles for cancer therapy.
Kim HJ; Kim A; Miyata K; Kataoka K
Adv Drug Deliv Rev; 2016 Sep; 104():61-77. PubMed ID: 27352638
[TBL] [Abstract][Full Text] [Related]
20. In vivo pharmacokinetics, tissue distribution and underlying mechanisms of various PEI(-PEG)/siRNA complexes.
Malek A; Merkel O; Fink L; Czubayko F; Kissel T; Aigner A
Toxicol Appl Pharmacol; 2009 Apr; 236(1):97-108. PubMed ID: 19371615
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
